Celsion Corp
F:CBOC
Relative Value
The Relative Value of one CBOC stock under the Base Case scenario is 0.032 EUR. Compared to the current market price of 0.286 EUR, Celsion Corp is Overvalued by 89%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
CBOC Competitors Multiples
Celsion Corp Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
C
|
Celsion Corp
F:CBOC
|
198.5m EUR | 0 | -13.9 | -13.5 | -13.3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
395.1B USD | 6.6 | 168.5 | 16.3 | 23.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
204.9B USD | 5.6 | 26.6 | 15.2 | 15.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
190B USD | 6.5 | 23.3 | 15.9 | 15.9 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121.3B USD | 10.4 | 33 | 24.3 | 25.4 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.5B USD | 5.7 | 18.3 | 15.6 | 17.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
87.4B AUD | 3.9 | 20.2 | 13.5 | 16.9 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR | 14 | 32.9 | 56 | 57.6 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |